Patents Represented by Attorney, Agent or Law Firm Genzyme Corporation
  • Transgene expression systems
    Patent number: 6485720
    Abstract: The present invention relates to transgene expression systems, related compositions comprising the transgene expression systems, and methods of making and using them. Preferred systems employ an adenovirus transgene expression vector comprising DNA encoding a transgene which codes for a desired product operably linked to expression control sequence, and at least a portion of the adenovirus E3 region and certain portions of the E4 region. The E4 portions comprise the open reading frame sequence known as E4ORF3 and at least one other portion of E4. Preferably the E4 portion of the vector (or “E4 cassette”) includes E4ORF3 and at least one other portion selected from E4ORF4, E4ORF6/7 and E4ORF3/4. The invention has a number of important features including improving persistency of transgene expression in a desired host cell.
    Type: Grant
    Filed: August 8, 2001
    Date of Patent: November 26, 2002
    Assignee: Genzyme Corporation
    Inventors: Johanne Kaplan, Donna Armentano, Richard J. Gregory
  • Method for identifying cytotoxic T-cell epitopes
    Patent number: 6338945
    Abstract: A method for isolating bio-active molecules from complex, rationally designed oligopeptide libraries which elicit cytolytic activity from cloned cytotoxic T lymphocytes (CTLs). The method allows the simultaneous screening of multiple CTL lines against indexed peptide libraries synthesized on solid phase support. Preferably decoding is not dependent on the presence of residual peptide and does not employ peptide sequencing. The method to identify CTL-reactive oligopeptides yields products of therapeutic value such as vaccines in treating cancers, viral diseases, and autoimmune diseases, as well as to identify useful clinical diagnostic reagents with a reduction in assay time and increase in throughput.
    Type: Grant
    Filed: December 11, 1997
    Date of Patent: January 15, 2002
    Assignee: Genzyme Corporation
    Inventor: Charles A. Nicolette
  • Method of purified rAAV vector production in non-human cell line transfected with cocksackie and adenovirus receptor
    Patent number: 6303371
    Abstract: The invention is directed to novel systems for the high level production of purified recombinant adeno-associated virus (rAAV) vector stocks comprising producer cell lines and helper adenoviruses. These systems provide high level production of rAAV vector stocks that are not contaminated by helper viruses or have very minimal contamination with helper virus. The invention is also directed to methods for the production of high yield, purified rAAV vector stocks using the systems of the invention.
    Type: Grant
    Filed: July 25, 2000
    Date of Patent: October 16, 2001
    Assignee: Genzyme Corporation
    Inventor: Samuel C. Wadsworth
  • Compositions containing polyanionic polysaccharides and hydrophobic bioabsorbable polymers
    Patent number: 6294202
    Abstract: Biocompatible compositions comprising polyanionic polysaccharides such as Hyaluronic Acid combined with hydrophobic bioabsorbable polymers as well as methods for making and using the compositions are described.
    Type: Grant
    Filed: October 6, 1994
    Date of Patent: September 25, 2001
    Assignee: Genzyme Corporation
    Inventors: James W. Burns, Keith E. Greenawalt, Louis Masi
  • Water insoluble derivatives of polyanionic polysaccharides
    Patent number: 6235726
    Abstract: A water insoluble, biocompatible composition that includes the reaction product of a polyanionic polysaccharide and an activating agent.
    Type: Grant
    Filed: August 18, 1999
    Date of Patent: May 22, 2001
    Assignee: Genzyme Corporation
    Inventors: James W. Burns, Robert Miller